Adalimumab-associated optic neuritis.
We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-alpha) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.
Chung
Jacob H
JH
Institute of Ophthalmology and Visual Science, UMDNJ-New Jersey Medical School, P.O. Box 1709, Newark, NJ 07101-1709, USA.
Van Stavern
Gregory P
GP
Frohman
Larry P
LP
Turbin
Roger E
RE
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D008875:Middle Aged; D009900:Optic Nerve / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D009902:Optic Neuritis / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D015354:Vision, Low / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D008776:Methylprednisolone Hemisuccinate; D000068879:Adalimumab